In cancer patients, Biopsies provide the histological explanation, of the disease and, currently, have revealed details of the genetic profile of the tumor enabling prediction of cancer progression and response to therapies. The role of CT-guided core biopsy has increased in the diagnosis of benign disease, cellular differentiation, and somatic mutation analysis. A fine-needle aspiration (FNA) biopsy is often used to take cell samples from organs or from lumps that are below the surface of the skin.
Being inherently unique, limited and non-renewable, after a limited number of analyses, small samples of tissue biopsies gets completely exhausted. A method has been introduced that enables fast and reproducible conversion of a small amount of tissue (approximating the quantity obtained by a biopsy) into a single, permanent digital file representing the mass spectrometry-measurable proteome of the sample. The method combines pressure cycling technology (PCT) and SWATH mass spectrometry (MS), and the resulting proteome maps can be analyzed, re-analyzed, compared and mined in silicon to detect and quantify specific proteins across multiple samples.
Bone marrow, mainly involves two separate specimens, a cytologic and a histologic preparation. Obtained by aspiration, cytologic preparation of bone marrow, allows better visualization of cell morphology, while histologic preparation, allows optimal evaluation of fibrosis, cellularity, or infiltrative disease. Bone marrow examination has been progressively useful in documenting metastatic connection of tumors. Sites like the posterior iliac crest, anterior iliac crest, the manubrium of the sternum and in some rare cases vertebral body can be used for the aspiration purpose.
Real-time monitoring of cancer therapies in individual patients can be achieved by the analysis of blood samples for circulating tumor cells (CTCs) or cell-free circulating tumor DNA (ctDNA). Elevated concentrations of ctDNA fragments are found in plasma and serum of cancer patients. The proportion of ctDNA to the entire blood free DNA differs in step with the location of cancer (low in Central system tumors), stage of cancer (higher in advanced cancers), type of cancers and detection ways. For detecting Circulating Tumor Cells, it can be enriched using various technologies like Cell Search system, CTC-Chip, MACS (Magnetic Activated Cell Sorting System), Adna Test and MagSweeper. Researches on combined analyses of CTCs and single DNA show a stimulating relationship between ctDNA and CTCs in blood and Disseminated tumor cells (DTCs) in bone marrow of cancer patients. Mutations, methylation, DNA integrity, microsatellite alterations, and infectious agent DNA may be detected in ctDNA, present in the blood of patients with tumors. Liquid Biopsy may be used for a range of clinical and analysis applications, together with response assessment in cuticular protein receptor (EGFR)-mutated NSCLC patients receiving EGFR amino acid enzyme substance medical care.
Importance & Scope:
Increasing incidence of cancer, need for minimally invasive medical procedures, and increased spending for effective treatments are the major factors driving the global biopsy market. Statistics published on Cancer shows that the global incidence of cancer in 2012 was 14.1 million which may reach to 23.6 million by 2030. The increasing number of cancer patients is set to increase the demand for biopsy procedures. Moreover, future projections indicate, even more, increase in prevalence, ensuring the lucrative industry growth in the coming years.
Market research analysts have estimated that the global biopsy devices market will keep on growing at a CAGR of more than 6% by 2020. Biopsy device Market Report predicts that the global biopsy market may reach $2,399 million by 2022, registering a CAGR of 5.5% during the period 2016-2022. According to the research report, the growing Non-Invasive Bone Marrow Aspiration Needle market is likely to boost the global market substantially over the forthcoming years. Bone Marrow Aspiration Needle Market will grow at CAGR of 7% by 2022. Revenue from the global bone marrow transplant market is estimated to expand at a constant CAGR of 3.9% over forecast period 2015–2021 and is expected to be valued at the US $10.3 Billion by the end of 2021.
Biopsy Market Segmentation, By Procedural Type :
- Needle biopsy
- Surgical biopsy
Needle biopsy market will grow at a CAGR of 5.2 % till 2023 for sure. Europe Clinical Reference Laboratory Market is projected to expand at a CAGR of 5.4% which may reach the US $ 1, 14,128.8 million by 2027. In 2016, Europe Clinical Reference Laboratory Market, Western Europe accounted for the largest market share.
- Boston Scientific Corporation
- Cook Medical
- CareFusion Corporation
- Hologic, Inc.
- Cardinal Health Inc.
- C. R. Bard Inc.
- Möller Medical GmbH
- Dickinson and Company
- Hakko co. ltd.
- Argon Medical Devices Inc.
Vacuum assisted needle biopsy has been estimated to be the fastest growing segment. According to the market study, the biopsy needle-based guns segments will have more influence in the biopsy devices throughout the forecast period and by 2020, will account for more than 41% of the total market share.
The surgical biopsy segment market value was $436.4 Million in 2015 and shared more than 56% of the total market and thus had more influence in the industry during 2015. The global breast biopsy market can smoothly reach $728.8 Million by 2020, at a CAGR of 10.8%.
The breast biopsy guidance market has been categorized as mammography, ultrasound, MRI, and others (PET and thermography). Owing to the increasing demand for minimally invasive and non-radiation breast biopsy among patients and surgeons, the ultrasound is estimated to be the fastest growing segment.
On the basis of region, the breast biopsy market is segmented into North Europe, Asia-Pacific, America, and the Rest of the World. North America accounted for the largest share of the breast biopsy market in 2015, followed by Europe. Asia-Pacific is expected to reach a higher rate of growth during the forecast period. The growth of the breast biopsy market in Asia-Pacific is mainly centered on India and China.
Major players operating in the market are:
- C.R. Bard
- Devicor Medical Products Inc. (U.S.)
- Company (U.S.)
- Inc. (U.S.)
- Hologic Inc. (U.S.)
Biopsy Market Segmentation, By Product Type:
- Biopsy guidance systems
- Biopsy needles
- Biopsy needle-based guns
- Biopsy forceps
According to an estimate, vacuum assisted needle biopsy is going to be the fastest growing segment. The biopsy needle-based guns segments will have the highest influence in the biopsy devices throughout the predicted period and will hold more than 41% of the total market share by 2020.
Biopsy Device Market, By Region:
North America contributed the global share by 55% in 2015 and thus was the largest regional industry in the field of biopsy devices, followed by Europe and Asia Pacific. U.S.In 2015, Biopsy devices market size has a value close to USD 1 billion, which was over 80% of the industries in North America. This was due to the increased awareness regarding cancer diagnosis, and continued funding activities for effective diagnostics procedures. Europe biopsy devices market share may see moderate growth, with Germany being responsible for over 28% sales in 2015. China and India biopsy devices market may enter the maximum growth rate of 11.8% from 2016 to 2024 and is eyed upon as the most beneficial market for investment.
Biopsy Device Market Analysis:
During the forecast period, CT-guided biopsy segment is expected to grow at the highest CAGR of 6.3%. The lung biopsy is expected to be the fastest growing application segment, entering a CAGR of 7.0%.The robotic guidance system segment is estimated to enter the highest CAGR of 7.0%.The Asia-Pacific region may become the fastest growing market, with a CAGR of 7.2%.
The key companies in the market are:
- Leica Biosystems
- C.R. Bard Inc.
- Boston Scientific Corporation
- Hologic Inc.
- and Company
- Ethicon EndoSurgery Inc.
- Mauna Kea Technologies
- Fujifilm Medical Systems
- Veran Medical Technologies
- Cook Medical Inc.
- Argon Medical Devices Inc,
- Intact Medical Corp.
Bone Marrow Market Analysis:
In 2014, autologous bone marrow transplant segment accounted for the major proportion of the market volume. During the forecast period; it is predicted to remain the leading segment in terms of volume. By disease indication, the leukemia segment is expected to have more influence over the market, having a share of 26.5% of the overall market revenue by the end of 2021. During the forecast period, Revenue contribution from the thalassemia segment may grow at the highest CAGR of 8.9%.
Based on regional segmentation, the market in Europe is supposed to continue the lead in the global market due to growing number of bone marrow transplant centers and expansion of bone marrow registry. Latin America market, due to increased density of bone marrow transplant centers, revenue is anticipated to grow at healthy CAGR of 6.0%. Bone Marrow Aspiration Needle Market is expected to grow at CAGR of 7% by 2022. It is likely to promote the global market significantly in the forthcoming years.
Top players in bone marrow transplantation market are:
- Merck Millipore Corporation,
- Sanofi-Aventis LLC,
- AllCells LLC
- Lonza Group Ltd.
- STEMCELL Technologies
- American Type Culture Collection (ATCC) Inc.
Top players in bone marrow needle market are:
- Argon Medical Devices
- Tsunami Medical
- Egemen International
- SOMATEX Medical Technologies
- Tenko International Group
- Zamar Biopsy
- Depuy Synthes
- Jorgensen Laboratories
Bone Marrow Biopsy Needle Industry scope on the basis of region:
- United States
- European Union
- Southeast Asia
Market Growth of Liquid Biopsy:
Major complications associated with typical tumor biopsies for a variety of various cancers include infections, colonic perforation, peritonitis, and collapsed respiratory organ, inflammation of the pancreas, sepsis, and haematoma. Moreover, within the current scenario, a diagnostic test prices between USD 2000 to as high as USD 10,000. The increase in prices due to further treatment needed owing to the complications could drive this value up fourfold.
The rising incidence of cancer, pros of liquid Biopsy test over solid tumor diagnostic test, advancements in the technology, handiness of funding and growing awareness regarding biopsy through government initiatives and the conferences, are driving the expansion of the market. Some within the business predict the market’s worth may balloon to anyplace from $20 billion to over $100 billion. The liquid biopsy market is anticipated to reach USD 1.66 Billion by 2021 from USD 0.58 Billion in 2016, growing at a CAGR of 23.4% during this period
- Biotechnology Companies
- Government and Public Laboratories
- Liquid Biopsy Product Manufacturers and Distributors
- Reference Laboratories
- Research Institutes
- Contract Research Organizations
- Research and Consulting Companies
- Pharmaceutical Companies
- Hospitals and Diagnostics Centers
A glance at Market of Advertising and Marketing
Multiple gene analysis using NGS technology expected to witness higher demand in this market over the forecast period. Some of the key players like Adaptive Biotechnologies, Biocept, Guardant Health, NeoGenomics Laboratories, Personal Genome Diagnostics, Qiagen, RainDance Technologies, Cynvenio, and Trovagene, have commercialized tests for CTC, ctDNA and exosomes and are directly involved in the liquid biopsy.
Commercialization is expected to take place that will consequently fuel significant growth in revenue between 2020 to 2030.The Global Liquid Biopsy Market to expand at a CAGR of 20.31% during the period 2017-2021.CTCs and ctDNA hold immense potential for breakthrough developments in cancer care and in reducing cancer-related mortality.